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OBJECTIVE — Womenwithdiabeteshaveahighincidenceandcomplicationrateofurinary
tract infections (UTIs). Our aims were to compare current treatment strategies with respect to
recurrence rates in women with diabetes with those without diabetes.
RESEARCH DESIGN AND METHODS — We used a Dutch registration database con-
taining pharmacy dispensing data. A total of 10,366 women with diabetes (17.5% premeno-
pausal) (aged 55 years) and 200,258 women without diabetes (68% premenopausal) who
received a ﬁrst course of trimethoprim, nitrofurantoin, fosfomycin, or norﬂoxacin between
January 1999 and January 2006 were included. We compared short (5 days) with long (5
days) prescriptions and norﬂoxacin with trimethoprim, nitrofurantoin, and fosfomycin. A re-
currence was deﬁned as a second prescription for one of the above-mentioned agents or a ﬁrst
with amoxicillin (clavulanic acid), ﬂuoroquinolones, or trimethoprim/sulfamethoxazole be-
tween 6 and 30 days after inclusion.
RESULTS — Premenopausal women with diabetes more often received a long (26.5 vs.
19.2%; P  0.001) treatment with norﬂoxacin (10.7 vs. 6.2%; P  0.001) but still had a higher
recurrence rate (16.1 vs. 12.2%; P  0.003) compared with those without diabetes. Similarly,
postmenopausalwomenwithdiabetesmoreoftenreceivedalonger(32.8vs.28.8%;P0.001)
treatment with norﬂoxacin (15.2 vs. 12.7%; P  0.001) but had a higher recurrence rate (19.1
vs. 16.4%; P  0.001) compared with those without diabetes.
CONCLUSIONS — Despite the fact that patients with diabetes more often received longer
and more potent initial treatment than patients without diabetes, pre- and postmenopausal
women with diabetes more often had recurrences of their UTIs.
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D
iabetes is an increasingly important
endocrine disease. Incidence of in-
fections is increased in diabetic
(type 1 and type 2) patients compared
with control subjects (1,2), and the uri-
nary tract is the most prevalent site of
these infections (3). Furthermore, dia-
betic patients with a urinary tract infec-
tion (UTI) more often develop severe and
rare complications, such as emphysema-
tous cystitis and papillary necrosis (4,5).
Studies addressing differences in UTI re-
currence rates between diabetic patients
and control subjects show contradictory
resultsforuncomplicatedlower(2,6)and
upper (7,8) UTIs. Currently, there are no
controlled clinical trials investigating the
optimal antimicrobial treatment strategy
in diabetic patients with UTIs. Current
recommendations rely on the opinion of
experts (5,9). It is generally recom-
mended to treat UTIs in diabetic patients
with antibiotics with high tissue penetra-
tion for 7–14 days. Importantly, we lack
data on the clinical practice of how dia-
betic patients with a UTI are actually
treated, to assess recurrence rates.
The aims of this study are to describe
the treatments (duration and agents) for
uncomplicated UTIs in women with and
without diabetes in the Netherlands and
to analyze recurrence rates of these UTIs
within 30 days after the last treatment.
RESEARCH DESIGN AND
METHODS
Database
Data were obtained from the PHARMO
Record Linkage System. The PHARMO
Institute is an independent scientiﬁc re-
searchorganizationdedicatedtostudying
druguseandoutcomesindailypracticein
the Netherlands. The PHARMO Record
Linkage System includes, among other
databases, the drug dispensing records
from community pharmacies linked to
hospital discharge records of more than 2
million community-dwelling inhabitants
of 40 demographically well-deﬁned
Dutch regions. For all residents, the com-
puterized drug dispensing histories con-
tain data concerning the dispensed drug,
prescriber specialty, dispensing date, dis-
pensed amount, prescribed dose regi-
mens, and the legend duration of use
(prescription length). All drugs are coded
according to the Anatomical Therapeutic
Chemical Classiﬁcation. The hospital
recordsincludedetailedinformationcon-
cerning the primary and secondary diag-
noses, procedures, and dates of hospital
admission and discharge. All diagnoses
are coded according to the ICD-9-CM
(available at http://www.pharmo.nl/).
Data between 1 January 1999 and 31 De-
cember 2005 were used.
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Dataofallwomenaged12years,receiv-
ing at least one prescription of tri-
methoprim, norﬂoxacin, nitrofurantoin,
or fosfomycin (6) in the period after the
ﬁrst of January 1999 and ﬁrst of January
2006 with follow-up data of at least 30
days, were extracted.
Following the Dutch guidelines, tri-
methoprim/sulfamethoxazole, amoxicil-
lin, and ﬂuorquinolones other than
norﬂoxacin are rarely prescribed for un-
complicated UTIs because of the high re-
sistance rates (available at http://
www.swab.nl) in the Netherlands or due
to the advice to preserve these antibiotics
for complicated UTIs.
Exclusion criteria
To limit the study population to women
with uncomplicated UTIs, we wanted to
exclude all women with possible recur-
rent UTIs because of secondary diseases
or underlying abnormalities. Therefore,
all factors that belong to the deﬁnition of
complicated UTIs (10) were considered
exclusion criteria:
● Pregnancy (delivery during the fol-
low-upperiodorfolicacidprescription
in the preceding year and during the
follow-up).
● Patientswithknownanatomicalabnor-
malities, for example, indwelling uri-
nary catheter or hospitalization for a
urethral stricture in the follow-up pe-
riod.
● The use of the following medication in
the preceding year and during the fol-
low-up: antiretroviral treatment for
HIV; immune suppressive drugs; che-
motherapy; and medication for renal
insufﬁciency, such as calcium binding
agents.
● Patients receiving a ﬁrst prescription
with duration of 30 days.
● Patients with a second prescription
within 5 days after their ﬁrst prescrip-
tion,indicatingacutesideeffectsorloss
of recipe or medication.
● Patients receiving in the preceding year
trimethoprim, norﬂoxacin, nitrofuran-
toin, or fosfomycin, indicating prophy-
laxis for recurrent UTIs.
Outcome parameters
The primary outcome was the prescrip-
tion for a second antibiotic course or a
hospitalization admission for a UTI dur-
ing the follow-up period.
Deﬁnitions
Thecohortentrydatewasdeﬁnedasthe
day that the patient received her ﬁrst
prescriptiontrimethoprim,norﬂoxacin,
nitrofurantoin, or fosfomycin. The his-
tory period was deﬁned as 1 year before
study inclusion. The follow-up period
was deﬁned as the duration of the ﬁrst
prescription plus 30 days after the co-
hort entry date. Patients with diabetes
were deﬁned by prescription of one or
more glucose-lowering medications
(tablets or insulin) in the history or in
the follow-up period.
Premenopausal women were deﬁned
as aged 55 years at the dispensing date
of their ﬁrst prescription. Postmeno-
pausal women were women aged 55
years at the moment of the dispensing
date of their ﬁrst prescription. This is a
conservative deﬁnition of postmeno-
pausalwomen,sincetheworldwidemean
age of menopause is 49.2 years.
A “new” diagnosis of UTI (inclusion
criteria for this study) was deﬁned as a
patient with no prescription for tri-
methoprim, norﬂoxacin, nitrofuran-
toin, or fosfomycin in the history (1
year) and a ﬁrst prescription for tri-
methoprim, norﬂoxacin, nitrofuran-
toin, or fosfomycin in the period from 1
January 1999 to 31 December 2005.
The ﬁrst prescription is always one of
the following antibiotics: trimethoprim,
norﬂoxacin,nitrofurantoin,orfosfomy-
cin. A recurrent UTI was deﬁned as a
prescription for trimethoprim, norﬂoxacin,
nitrofurantoin, or fosfomycin or amoxi-
cillin, ﬂuoroquinolones, amoxicillin/
clavulanic acid, or trimethoprim/sul-
famethoxazole in the follow-up period (5
days after the ﬁrst prescription until 30
days after the end of the ﬁrst prescription)
or hospitalization admission with the
diagnosisofaUTI.Theserecurrencescould
be relapses (second infection with the same
organism) or reinfections (second infection
with a different organism). Hospital admis-
sions were included as cases diagnosed
accordingtotheICD-9systemwitheithera
kidney infection (590), cystitis (595), ure-
thritis(notsexuallytransmitted)(597),ure-
thral syndrome (597), or other disorders of
urethra and urinary tract (599).
Some of the above-mentioned antibi-
otics for a recurrent UTI could also be
used for other diseases than UTIs. To ex-
clude antibiotics prescriptions for other
infections than a UTI, all analyses were
repeated with the use of comedication,
deﬁned as medication given at the same
moment as the antibiotic for a recurrent
UTI from one of the following anatomical
therapeutic chemical groups: A (gastro-
intestinal),D(skin),R(respiratory),andS
(ear or eye). Similarly, analyses were re-
peated with prescriptions from other
specialties than general practitioners
excluded.
Aggressive treatment for a UTI was
deﬁned as a treatment with an antibiotic
thathashightissuepenetration(inkidney
and prostate). For the ﬁrst prescription
agents only, norﬂoxacin has this potency.
Statistical analyses and ethics
Data were analyzed using SPSS software
for Windows, version 14.0. Medication
use and recurrence rate were compared
between women with and without diabe-
tes.Analysesweredonewitha
2test.We
corrected for age by comparing different
age strata. A P value 0.05 was consid-
ered to be statistically signiﬁcant.
Ethical approval was not necessary
because all data were anonymized before
entering the PHARMO database. Re-
searchers only have information on sex
and age of the patient. All other identify-
ing information is deleted after the link-
age with the hospital records from the
national registry. This approach has been
approved by the Dutch Data Protection
Authority (6).
RESULTS
Inclusion criteria
Initially, the database consisted of
246,306 women who were aged 12
years and received a prescription for tri-
methoprim, norﬂoxacin, nitrofurantoin,
orfosfomycininthestudyperiod(Fig.1).
Exclusion criteria
A total of 21,808 women were excluded
for different reasons (Fig. 1), and another
15,539 women were excluded because
they had a UTI in the year before the co-
hort entry date. Finally, the study in-
cluded 210,624 women: 10,366 women
with diabetes (17.5% premenopausal
women aged 55 years) and 200,258
women without diabetes (68% premeno-
pausal).
Premenopausal women
Baseline characteristics of the premeno-
pausal women are shown in Table 1. Per-
centage of prescriptions with norﬂoxacin
were signiﬁcantly higher and the treat-
ment duration was signiﬁcantly longer in
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compared with those without. The recur-
rence rate (Table 2) was signiﬁcantly
higher in premenopausal women with di-
abetes: 16.1% in women with diabetes
and 12.2% in women without diabetes
(P  0.002). There was no signiﬁcant
difference between hospitalization of
womenwithandwithoutdiabetes(0.1vs.
0.1%, P  0.790). In both analyses, the
results were similar in age strata.
Postmenopausal women
Baseline characteristics of the postmeno-
pausal women are shown in Table 1. Per-
centage prescriptions with norﬂoxacin
were signiﬁcantly higher and the treat-
ment duration was signiﬁcantly longer in
postmenopausal patients with diabetes
compared with those without. The recur-
rence rate (Table 2) was signiﬁcantly
higher in postmenopausal women with
diabetes: 19.1% in women with and
16.4% in women without diabetes (P 
0.001). There was a signiﬁcant difference
in hospitalization frequency between
postmenopausal women with and with-
out diabetes (0.3 vs. 0.2%, P  0.003). A
total of 23 the postmenopausal women
with diabetes and 83 without diabetes
were hospitalized because they had an in-
fection of the kidneys or other disorder of
the urinary tract. In both analyses, the re-
sults were similar in age strata.
Secondary analyses
Therapeutic courses given to diabetic
(DM group) or nondiabetic (DM
group) pre- or postmenopausal women
were consistent with the Dutch guide-
lines (see CONCLUSIONS) in 71% (pre-
menopausal DM women), 79.8%
(premenopausal DM women), 51.8%
(postmenopausal DM women), and
55.4% (postmenopausal DM women)
of the cases.
General practitioners prescribed
92.0–96.1% of the antimicrobials in all
patient groups. When all analyses were
repeated with only the prescriptions by
the general practitioners, similar results
were found. The same was true when all
Figure 1—Numbers of included and excluded women in the total study group.
Antibiotic prescription proﬁle, UTIs, and diabetes
1382 DIABETES CARE, VOLUME 31, NUMBER 7, JULY 2008analyses were repeated after excluding
patients who were using comedication at
the time of the antibiotic prescription.
CONCLUSIONS — In this study, we
foundthatbothpre-andpostmenopausal
women with diabetes receive longer and
more potent antimicrobial treatment for
uncomplicated UTIs compared with pre-
and postmenopausal women without
diabetes. However, despite this more
aggressive treatment, both pre- and post-
menopausal women with diabetes had
more recurrences of their UTIs than
women without diabetes. Besides that,
hospitalization for complications of the
UTI was signiﬁcantly more often seen in
postmenopausal women with diabetes.
The choice for a more potent antibi-
oticwasnottotreatarecurrentUTI,since
all patients with a UTI in the previous 12
months were excluded. The percentages
ofwomenwitharecurrentUTIwerecom-
parablewiththeresultsfoundbyLawren-
son et al. (7), who demonstrated that
overall 14% of 75,045 newly treated pa-
tients with a UTI (0.7% of all patients had
diabetes) received a second antibiotic
within 28 days.
The longer prescription period for di-
abetic patients with an uncomplicated
UTI with norﬂoxacin is not in accordance
with the national Dutch guideline in use
inthestudyperiod.Therecommendation
in the national Dutch guideline 1999 in
use during the study period for an un-
complicated UTI was a 3-day oral antimi-
crobial regimen with either 100 mg
nitrofurantoin three times daily or 300
mg trimethoprim once daily for patients
with and without diabetes (11). There
werenodifferencesinantimicrobialresis-
tance percentages of causative uropatho-
gens, isolated in the same period as the
dataofthepresentstudy,betweenwomen
with and without diabetes (12). Treating
physicians may have been chosen for
longer treatment duration and a more ag-
gresive antibiotic due to the higher risk of
complications of UTIs.
Postmenopausal women with diabe-
tesweresigniﬁcantlymoreoftenadmitted
to the hospital than women without dia-
betes. These results are comparable with
those from a Canadian study that demon-
strated that patients with diabetes more
often had a hospitalization or physician
claims for an infectious disease than pa-
tients without diabetes (1). However, in
contrast to the mortality rate outside the
hospital,themortalityrateinsidethehos-
pital is not higher in patients with diabe-
tes (1,3). Therefore, it seems possible that
physicians refer patients with diabetes
faster and treat them more aggressively in
thehospitalcomparedwithpatientswith-
out diabetes.
To our knowledge, this is the ﬁrst
study of its kind with this amount of
Table 1—Treatment of UTIs in pre- and postmenopausal women with and without diabetes
Premenopausal women Postmenopausal women
With diabetes Without diabetes P value With diabetes Without diabetes P value
n 1,817 136,195 8,549 64,063
Age (years) 47 (38–52) 34 (23–44) 75 (67–81) 70 (62–79)
Use of insulin (%) 892 (49.1) 0 2,830 (33.1) 0
Use of oral antidiabetes
medications (%)
1,163 (64.0) 0 6,841 (80.0) 0
Trimethoprim (%) 773 (42.5) 63,094 (46.3) 0.001 3,499 (40.9) 27,573 (43.0) 0.001
Nitrofurantoin (%) 847 (46.6) 64,357 (47.3) 0.588 3,737 (43.7) 28,239 (44.1) 0.520
Fosfomycin (%) 2 (0.1) 245 (0.2) 0.484 15 (0.2) 136 (0.2) 0.483
Norﬂoxacin (%) 195 (10.7) 8,499 (6.2) 0.001 1,298 (15.2) 8,115 (12,7) 0.001
Treatment duration 5 days 1,336 (73.5) 110,024 (80.8) 0.001 5,748 (67.2) 45,617 (71.2) 0.001
Treatment duration 5 days 481 (26.5) 26,171 (19.2) 0.001 2,801 (32.8) 18,446 (28.8) 0.001
Data are n (%) or median (25th to 75th percentile).
Table 2—Recurrence rates and treatment of a recurrent UTI in pre- and postmenopausal women with and without diabetes
Premenopausal women Postmenopausal women
With diabetes Without diabetes P value With diabetes Without diabetes P value
n 1,817 136,195 8,549 64,063
Second prescription (%) 292 (16.1) 16,586 (12.2) 0.002 1,636 (19.1) 10,498 (16.4) 0.001
Hospitalization (%) 2 (0.1) 124 (0.1) 0.790 25 (0.3) 97 (0.2) 0.003
Trimethoprim (%)* 53 (18.2) 3,176 (19.1) 0.667 306 (18.7) 1,871 (17.8) 0.387
Nitrofurantoin (%)* 82 (28.1) 5,848 (35.3) 0.011 476 (29.1) 3,153 (30.0) 0.440
Fosfomycin (%)* 0 (0.0) 37 (0.2) 0.419 1 (0.1) 24 (0.2) 0.165
Norﬂoxacin (%)* 54 (18.5) 2,449 (14.8) 0.076 351 (21.5) 2,252 (21.5) 0.998
Amoxicillin (%)* 28 (9.6) 1,603 (9.7) 0.965 112 (6.8) 664 (6.3) 0.423
Amoxicillin/clavulanic acid (%)* 26 (8.9) 1,192 (7.2) 0.261 129 (7.9) 716 (6.8) 0.116
Trimethoprim/sulfamethoxazole (%)* 22 (7.5) 1,183 (7.1) 0.792 97 (5.9) 784 (7.5) 0.026
Ciproﬂoxacin (%)* 17 (5.8) 783 (4.7) 0.380 120 (7.3) 774 (7.4) 0.957
Fluoroquinolones (%)*† 10 (3.4) 315 (1.9) 0.060 44 (2.7) 260 (2.5) 0.608
Data are n (%). *Percentages from second prescription. †Without norﬂoxacin and ciproﬂoxacin.
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tion, in contrast to most earlier studies in
which the recurrence rate of UTIs were
described (2,6,7), we also compared the
different treatment strategies between
women with and without diabetes and
analyzed pre- and postmenopausal
women separately. The risk factors for
UTIs are partly different in pre- and post-
menopausal women (13,14), and there-
fore they should not be regarded as
identical entities. Furthermore, it is only
possible to interpret the recurrence rates
whentheinitialtreatmentstrategiesofthe
two groups are known.
This study has several limitations. In
the ﬁrst place, it is retrospective and we
do not have records on what the reasons
of the treating physician were when pre-
scribingaspeciﬁcantimicrobialagentora
longer treatment duration. It can be pos-
siblethatdiabeticpatientsmoreoftenhad
symptoms of a UTI with tissue invasion
(pyelonephritisorurosepsis)(15,16).We
have shown before that only 0.5% of dia-
betic patients with a UTI had clinical
symptoms of a pyelonephritis (17) com-
pared with 0.2% in control subjects. Oth-
ers have demonstrated that the risk ratio
for pyelonephritis in patients with com-
pared with those without diabetes ranges
from 1.86 to 4.4 (18,19). These numbers
make clear that even when more women
with diabetes had clinical symptoms of a
pyelonephritis and therefore were treated
with norﬂoxacin during a longer period,
this cannot totally explain the demon-
strated differences. It therefore seems
likelythatthephysiciantookdiabetessta-
tus into account when prescribing antibi-
otic therapy. Based on drug-dispensing
data, we may have missed diabetic
women treated with diet and exercise
only. On the other hand, we know that
many patients with diabetes are not diag-
nosed (20), so any deﬁnition of diabetes
in this type of database research has im-
perfections. Furthermore, it is not possi-
bletodistinguishbetweentype1andtype
2 diabetes because patients in both
groups could receive a treatment with in-
sulin. This division is, for this study, not
that important because in an earlier study
(21) we showed a comparable incidence
of UTI in patients with type 1 and type 2
diabetes. Unfortunately, because we did
not have urine culture results, we were
not able to distinguish between a relapse
andareinfection,whichcouldhaveinﬂu-
enced the subsequent treatment decision.
Furthermore, because follow-up was
only 30 days, it is possible that pregnant
women might have been misclassiﬁed
(deliveryafter30days).Anotherlimita-
tion is that the level of sexual activity was
unknown despite the fact that this is an
important risk factor for UTI in premeno-
pausal women. However, we do not ex-
pect that a higher percentage of pregnant
women (and therefore women with a
complicated UTI) were included in the
diabetic women group or that diabetic
women had a higher frequency of sexual
intercourse. Moreover, pregnant women
withaUTIaremostlytreatedwithamoxi-
cillin/clavulanic acid or a cephalosporin
in the Netherlands and therefore would
nothavebeenincludedinthisstudyatall.
Therefore, it is unlikely that this possible
misclassiﬁcationorlackofinformationon
risk factors would have inﬂuenced our
results.
Furthermore, no differences were
found after analyzing only the prescrip-
tionsofthegeneralpractitioners.Another
limitation is that women with a recur-
rence could have underlying anatomical
abnormalities like bladder neuropathy.
Therefore, we excluded all women who
had a UTI in the previous year to mini-
mize this group.
In conclusion, we showed that both
pre-andpostmenopausalwomenwithdi-
abetesandaUTIreceiveamoreaggressive
and longer treatment but still have more
recurrences of their UTIs than women
withoutdiabetes.Whethertherapywitha
longer duration or an antibiotic with high
tissuepenetrationcontributestolowerre-
currence rates needs further investigation.
Therefore, a prospective randomized con-
trol trial with different treatment strategies
must determine which treatment strategy is
optimal in diabetic women with a UTI.
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